Havila Shipping ASA: Kontraktsforlengelse for PSVene Havila Borg og Havila Herøy med Peterson den Helder BV
Peterson den Helder BV har erklært 12 måneders opsjon for PSVene Havila Borg og Havila Herøy.
Forlengelsen gjelder fram til April 2024
Kontakt:
Administrerende direktør Njål Sævik, +47 909 35 722
Finansdirektør Arne Johan Dale +47 909 87 706
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.
Om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeldinger fra GlobeNewswire by notified
Registrer deg med din e-postadresse under for å få de nyeste sakene fra GlobeNewswire by notified på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra GlobeNewswire by notified
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose
Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse
Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor
Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse
NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5
Ress Life Investments A/S publishes notice for Annual General Meeting28.3.2023 10:44:14 CEST | Press release
Ress Life Investments A/S Nybrogade 12 1203 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 28 March 2023 Corporate Announcement 11/2023 Ress Life Investments A/S publishes notice for Annual General Meeting TO THE SHAREHOLDERS OF RESS LIFE INVESTMENTS A/S In accordance with Article 9.8 of the Articles of Association, notice is hereby given of the Annual General Meeting of Ress Life Investments A/S (the "Company") which will take place on Wednesday 19 April 2023 at 10.00 a.m. at Nybrogade 12, 1203 Copenhagen K, Denmark. Shareholders in the Company are invited to participate. Agenda for the Annual General Meeting: 1) Adoption of the annual report 2) Appropriation of profit or loss as recorded in the adopted annual report 3) Election of members of the Board of Directors 4) Approval of the Remuneration Report 5) Approval of remuneration for the Board of Directors for the financial year 2023 6) Authorisation to the board of directors to purchase
Spar Nord explores the potential for issuing Tier 2 capital28.3.2023 10:40:24 CEST | Press release
As an element in its ongoing endeavours to optimize the Bank’s capital structure and secure appropriate capital resources, Spar Nord has decided to explore the potential for issuing new Tier 2 capital. In this connection, Spar Nord has mandated Nykredit as Arranger and Nykredit and Spar Nord Bank as Joint Bookrunners to assess market interest for the potential issue. Subject to market conditions and investor feedback, a Tier 2 capital issue in DKK with a term to maturity of 10 years and the option of prepayment at par 5 years after the date of issuance (subject to regulatory approval), documented with Spar Nord’s EMTN program dated 9 March 2023, listed on Euronext in Dublin may follow. Please direct any questions regarding this release to Rune Brandt Børglum, Head of Investor Relations, on tel. + 45 9634 4236, or by e-mail at rsn@sparnord.dk. Rune Brandt Børglum Head of Investor Relations Attachment No. 19 - Spar Nord explores the potential for issuing Tier 2 capital